Drug Trial Radar · NCT00622284
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,560
Actual
Start
Feb 2008
Primary completion
Dec 2010
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably \> 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control
Conditions
- Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mgDrug
Placebo tablet once daily
Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mgDrug
Placebo tablets once daily
BI 1356Drug
5mg, once daily in the morning for 104 weeks
GlimepirideDrug
1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c Change From Baseline at Week 52Time frame: Baseline and week 52
- HbA1c Change From Baseline at Week 104Time frame: Baseline and week 104
Locations
221 sites in 16 countries. Site status is shown where the registry gives one.
1218.20.10033 Boehringer Ingelheim Investigational Site
Tempe, Arizona
1218.20.10003 Boehringer Ingelheim Investigational Site
Chula Vista, California
1218.20.10020 Boehringer Ingelheim Investigational Site
Los Angeles, California
1218.20.10035 Boehringer Ingelheim Investigational Site
Los Angeles, California
1218.20.10037 Boehringer Ingelheim Investigational Site
Los Gatos, California
1218.20.10034 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
1218.20.10023 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
1218.20.10030 Boehringer Ingelheim Investigational Site
Topeka, Kansas
1218.20.10028 Boehringer Ingelheim Investigational Site
St Louis, Missouri
1218.20.10006 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
1218.20.10022 Boehringer Ingelheim Investigational Site
Endwell, New York
1218.20.10032 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1218.20.10031 Boehringer Ingelheim Investigational Site
Columbus, Ohio
1218.20.10013 Boehringer Ingelheim Investigational Site
Mentor, Ohio
1218.20.10045 Boehringer Ingelheim Investigational Site
Perrysburg, Ohio
1218.20.10042 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma
1218.20.10024 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania
1218.20.10002 Boehringer Ingelheim Investigational Site
Greer, South Carolina
1218.20.10007 Boehringer Ingelheim Investigational Site
San Antonio, Texas
1218.20.10036 Boehringer Ingelheim Investigational Site
Murray, Utah
1218.20.10029 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah
1218.20.10009 Boehringer Ingelheim Investigational Site
Federal Way, Washington
1218.20.10026 Boehringer Ingelheim Investigational Site
Renton, Washington
1218.20.35201 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.20.35202 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.20.35203 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.20.35207 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.20.35204 Boehringer Ingelheim Investigational Site
Stara Zagora, Bulgaria
1218.20.45006 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
1218.20.45001 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
1218.20.45011 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
1218.20.45013 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
1218.20.45002 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
1218.20.45003 Boehringer Ingelheim Investigational Site
København NV, Denmark
1218.20.45007 Boehringer Ingelheim Investigational Site
Odense, Denmark
1218.20.3308A Boehringer Ingelheim Investigational Site
Joué Les Tours, France
1218.20.3308C Boehringer Ingelheim Investigational Site
Joué Les Tours, France
1218.20.3308D Boehringer Ingelheim Investigational Site
Joué Les Tours, France
1218.20.3308E Boehringer Ingelheim Investigational Site
Joué Les Tours, France
1218.20.3308F Boehringer Ingelheim Investigational Site
Joué Les Tours, France
Showing 40 of 221 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.